BIONUMERIK $6 MIL. DRUG DESIGN CRADA WITH LAWRENCE LIVERMORE LAB
Executive Summary
BIONUMERIK $6 MIL. DRUG DESIGN CRADA WITH LAWRENCE LIVERMORE LAB will focus on developing faster pharmaceutical discovery software able to run on high-performance parallel computer systems for the design of cancer and cardiovascular drugs. At a June 15 Capitol Hill press conference held by Sen. Boxer (D-Calif.), and Everet Beckner, PhD, principal deputy assistant secretary for defense programs for the Department of Energy, which runs Lawrence Livemore National Laboratory, said DoE would provide $3 mil. over three years toward the research, with San Antonio-based BioNumerik contributing the remaining $3 mil.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth